Ardelyx Croissance future
Future contrôle des critères 5/6
Ardelyx is forecast to grow earnings and revenue by 69.5% and 26.5% per annum respectively. EPS is expected to grow by 69.5% per annum. Return on equity is forecast to be 2.9% in 3 years.
Informations clés
69.5%
Taux de croissance des bénéfices
69.5%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 27.1% |
| Taux de croissance des recettes | 26.5% |
| Rendement futur des capitaux propres | 2.9% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 02 Nov 2024 |
Mises à jour récentes de la croissance future
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 03
Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 04Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 04Recent updates
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 03Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business
Oct 24Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?
Aug 25Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Aug 07Ardelyx Faces Rising Challenges Despite Revenue Growth
Aug 05Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 04Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook
Jul 13Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge
Jul 05Ardelyx: Strong Execution, Fairly Valued
May 10Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 04Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)
May 03Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing
Apr 17Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Mar 13Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 24Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance
Feb 20Ardelyx's XPHOZAH Still An Afterthought To The Pros
Jan 31Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement
Jan 10Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price
Jan 04Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt
Dec 14Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Aug 03Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt
Jul 31Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now
Apr 17Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Mar 30Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Dec 14What To Expect For Ardelyx In The Coming Month
Oct 18Ardelyx: Potential For Growth, But Must Strengthen Its Financial Position
Oct 04Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 531 | 130 | 160 | 165 | 9 |
| 12/31/2025 | 388 | -16 | N/A | 42 | 10 |
| 12/31/2024 | 326 | -42 | N/A | -70 | 10 |
| 9/30/2024 | 252 | -73 | -64 | -63 | N/A |
| 6/30/2024 | 210 | -65 | -86 | -85 | N/A |
| 3/31/2024 | 159 | -66 | -81 | -81 | N/A |
| 12/31/2023 | 124 | -66 | -90 | -90 | N/A |
| 9/30/2023 | 134 | -27 | -67 | -67 | N/A |
| 6/30/2023 | 83 | -56 | -71 | -71 | N/A |
| 3/31/2023 | 63 | -66 | -87 | -87 | N/A |
| 12/31/2022 | 52 | -67 | -70 | -70 | N/A |
| 9/30/2022 | 9 | -114 | -124 | -124 | N/A |
| 6/30/2022 | 5 | -135 | -133 | -133 | N/A |
| 3/31/2022 | 4 | -153 | -137 | -136 | N/A |
| 12/31/2021 | 10 | -158 | -154 | -153 | N/A |
| 9/30/2021 | 11 | -151 | -133 | -131 | N/A |
| 6/30/2021 | 12 | -125 | -118 | -116 | N/A |
| 3/31/2021 | 13 | -105 | -102 | -101 | N/A |
| 12/31/2020 | 8 | -94 | -82 | -81 | N/A |
| 9/30/2020 | 8 | -85 | -75 | -75 | N/A |
| 6/30/2020 | 8 | -91 | -76 | -76 | N/A |
| 3/31/2020 | 6 | -91 | -85 | -85 | N/A |
| 12/31/2019 | 5 | -95 | -77 | -76 | N/A |
| 9/30/2019 | 3 | -103 | -84 | -84 | N/A |
| 6/30/2019 | 0 | -104 | -91 | -90 | N/A |
| 3/31/2019 | 0 | -100 | -81 | -80 | N/A |
| 12/31/2018 | 3 | -91 | -71 | -70 | N/A |
| 9/30/2018 | 45 | -53 | -47 | -47 | N/A |
| 6/30/2018 | 44 | -50 | N/A | -39 | N/A |
| 3/31/2018 | 44 | -53 | N/A | -45 | N/A |
| 12/31/2017 | 42 | -64 | N/A | -65 | N/A |
| 9/30/2017 | N/A | -106 | N/A | -97 | N/A |
| 6/30/2017 | N/A | -114 | N/A | -102 | N/A |
| 3/31/2017 | N/A | -117 | N/A | -103 | N/A |
| 12/31/2016 | N/A | -112 | N/A | -93 | N/A |
| 9/30/2016 | N/A | -98 | N/A | -87 | N/A |
| 6/30/2016 | N/A | -87 | N/A | -75 | N/A |
| 3/31/2016 | 18 | -50 | N/A | -80 | N/A |
| 12/31/2015 | 24 | -30 | N/A | -72 | N/A |
| 9/30/2015 | 30 | -16 | N/A | -54 | N/A |
| 6/30/2015 | 38 | 2 | N/A | -48 | N/A |
| 3/31/2015 | 29 | -6 | N/A | 6 | N/A |
| 12/31/2014 | 32 | -3 | N/A | 13 | N/A |
| 9/30/2014 | 34 | -4 | N/A | 28 | N/A |
| 6/30/2014 | 33 | -5 | N/A | 34 | N/A |
| 3/31/2014 | 31 | -7 | N/A | 5 | N/A |
| 12/31/2013 | 29 | -7 | N/A | 2 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ARDX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Bénéfices vs marché: ARDX is forecast to become profitable over the next 3 years, which is considered above average market growth.
Croissance élevée des bénéfices: ARDX is expected to become profitable in the next 3 years.
Chiffre d'affaires vs marché: ARDX's revenue (26.5% per year) is forecast to grow faster than the US market (8.9% per year).
Croissance élevée des revenus: ARDX's revenue (26.5% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: ARDX's Return on Equity is forecast to be low in 3 years time (2.9%).